Replies to post #7698 on RespireRx Pharmaceuticals Inc (fka RSPI)

[neuroinv]

<I didn't make the asinine remark about letters to your Congressman. That was uncalled for and you know it.>>

While my use of sarcasm may be in dubious taste, Congress is the only authority to which the FDA sees itself as beholden. Everyone else comes in on their knees with their hands raised in supplication. You may not like it, but that's the reality. Hence the tongue-in-cheek reference.

As to my participating in a "tone of intolerance" --I don't see it that way at all. I have generally in the past been supportive of Gfp's frequently very useful contributions. There are times he goes to one or extreme or the other, and I'm not a fan of either manic euphoria or doom-and-gloom. But even the latter serves a purpose, so long as it is not overly repetitive, and does not end up with a search for a messenger to be shot. Especially if it's me. And I will respond with an edge if attacked, or if off-the-wall requests like 'tell us who your sources are' are made.

<<Recently on this board, I find there is alot more cheerleading and alot less rational discussion. It's beginning to look more like a YMB everyday. >>

You've got to be kidding. I took a look at the YMB for Cortex a couple of weeks ago. it was like looking into the back ward of an old state mental hospital. There is no resemblance, in my eyes.

NeuroInvestment

[gfp927z]

Blade, OT - BTW, what do you think of Pharmion and Spectrum as investments at these prices? Spectrum wasn't necessarily going to get that much from Satraplatin anyway in the grand scheme of things, though their co-promote option might have been valuable and they did have some royalties. Satraplatin might still get approved eventually, once they've gotten the rest of the data. Pharmion had some good news at ASCO for one of their other compounds that sounded very promising. GPC is the one with the really big Satraplatin exposure. I haven't followed Spectrum that closely, but they have a bunch of other "irons in the fire", including (from my somewhat dated notes) Levofolinic Acid, Sumatriptan, Elsamitrucin, Eoquin, Ozarelix, Lucanthone, Renazorb, several others, plus their generic business, and their CEO seems like a sharp and resilient type, who has managed to avoid dilution over the years.

[money4retirement]

"my disappointment and recent frustration with this board has been the way that gfp has been treated by others..." "There seems to be an underlying tone of intolerance..."
-------------------------------------------------------------

well, i think RBlatch reply to gfp sums it up --

"You stated your opinion and concerns and that is fine. Then you restated them each and every time someone else stated their counter opinion. Over and over and over and over."

We on this board appreciate your input and commentary regarding this stock, however..."
--------------------------------------------------------------
so Bladerunner, ask not what intolerance can do for you, ask what you can do for intolerance.

i'm sure when cortex's pps moves to the $5 range (hopefully soon) this will become a kinder, gentler message board.

fred
(tolerating the intolerable)


Rodney King, Bio Investor Guru: "Can't we all just get along."